Hims & Hers Health (NYSE:HIMS) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Hims & Hers Health (NYSE:HIMS) from a hold rating to a sell rating in a research note released on Saturday.

Several other research analysts also recently commented on HIMS. Bank of America boosted their target price on Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 4th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Finally, UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Reduce” and a consensus target price of $45.27.

Hims & Hers Health Stock Down 1.2%

Shares of HIMS opened at $41.04 on Friday. The firm has a 50 day simple moving average of $51.28 and a two-hundred day simple moving average of $51.00. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 4.46. Hims & Hers Health has a one year low of $19.15 and a one year high of $72.98. The company has a market cap of $9.28 billion, a P/E ratio of 76.00, a P/E/G ratio of 8.07 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. During the same quarter in the previous year, the business posted $0.32 EPS. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Activity

In related news, CFO Oluyemi Okupe sold 145,000 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares of the company’s stock, valued at $7,139,264.40. This trade represents a 52.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Chi sold 13,749 shares of the company’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $694,324.50. Following the completion of the sale, the insider owned 297,139 shares in the company, valued at $15,005,519.50. This trade represents a 4.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 712,271 shares of company stock valued at $37,631,985. Insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. increased its position in Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after purchasing an additional 2,128,587 shares during the period. Nuveen LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $58,403,000. Clear Street LLC bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $83,582,000. Norges Bank acquired a new stake in shares of Hims & Hers Health during the second quarter worth $78,464,000. Finally, Marex Group plc acquired a new stake in shares of Hims & Hers Health during the second quarter worth $53,626,000. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.